Effect of oral contraceptives on the transport of chlorpromazine across the CACO-2 intestinal epithelial cell line

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 56, Issue 2, 2003, Pages 159-165

  Brown, Deon ^a   Goosen, Theunis C ^b   Chetty, Mano ^c   Hamman, Josias H ^a  

^a TSHWANE UNIVERSITY OF TECHNOLOGY   (South Africa)

^b NORTH WEST UNIVERSITY   (South Africa)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Allosteric interaction; Caco 2 cells; Chlorpromazine; Ethinyloestradiol; P glycoprotein; Progesterone

Indexed keywords

CHLORPROMAZINE; ETHINYLESTRADIOL; GLYCOPROTEIN P; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; STEROID HORMONE; VERAPAMIL;

ALLOSTERISM; ARTICLE; CELL LINE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BINDING SITE; DRUG EFFECT; DRUG TRANSPORT; EXPERIMENTAL MODEL; HORMONE BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; INTESTINE EPITHELIUM CELL; STATISTICAL SIGNIFICANCE;

EID: 0042836879     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(03)00110-3     Document Type: Article

References (20)

1. Chetty M., Miller R. Oral contraceptives increase the plasma concentrations of chlorpromazine: case report. Ther. Drug Monit. 23:2001;556-558.
2. Lindamer L.A., Buse D.C., Lohr J.B., Jeste D.V. Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol. Psychiatry. 49:2001;47-57.
3. Benet L.Z., Izumi T., Zhang Y., Silverman J.A., Wacher V.J. Intestinal MDR transport proteins and P450 enzymes as barriers to oral drug delivery. J. Control. Release. 62:1999;25-31.
4. Romsicki Y., Sharom F.J. The ATPase and ATP-binding functions of P-glycoprotein. Eur. J. Biochem. 256:1998;170-178.
5. Dale Y.K. The contribution of P-glycoprotein to pharmacokinetic drug-drug interaction. J. Clin. Pharmacol. 39:1999;1203-1211.
6. Krishna R., Mayer L.D. Multidrug resistance in cancer, mechanisms, reversal using modulators of multidrug resistance and the role of multidrug resistance modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11:2000;265-283.
7. Ruetz S., Gros P. A mechanism for P-glycoprotein action in multidrug resistance: are we there yet? Trends Pharmacol. Sci. 15:1994;260-263.
8. Roa U.S., Scarborough G.A. Direct demonstration of high affinity interactions of immunosuppresent drugs with the drug binding site of the human P-glycoprotein. Mol. Pharmacol. 45:1994;773-776.
9. Ford J.M., Bruggenmann E.P., Pastan I., Gottesman M.M., Hait W.N. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res. 50:1990;1748-1756.
10. Syed S.K., Christopherson R.I., Roufogalis B.D. Chlorpromazine transport in membrane vesicles from multidrug resistant CCRF-CEM cells. Biochem. Mol. Biol. Int. 39:1996;687-696.
11. Stein W.D. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol. Rev. 77:1997;545-590.
12. Higgins C.F., Gottesman M.M. Is the multidrug transporter a flippase? Trends Biochem. Sci. 17:1992;18-21.
13. Shapiro A.B., Fox K., Lam P., Ling V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Eur. J. Biochem. 259:1999;841-850.
14. Martin C., Berridge G., Higgins C.F., Mistry P., Charlton P., Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 58:2000;624-632.
15. Augustijns P.F., Bradshaw T.P., Gan L.L., Hendren R.W., Thakker D.R. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporin a transport. Biochem. Biophys. Res. Commun. 197:1993;360-365.
16. Janse Van Vuuren C.A. An Investigation into Optimising the Bioavailability of Cyclosporine by Using Caco-2 Cell Lines. 2000;PU for CHE, Thesis-M Sc, Potchefstroom.
17. Ueda K., Okamura N., Hirai M., Tanigawara Y., Saeki T., Kioka N., Komano T., Hori R. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem. 267:1992;24248-24252.
18. The National Formulary, USP 25: NF 20. 2002;United States Pharmacopoeial Convention, Inc, Rockville, MD.
19. Garrigos M., Mir L.M., Orlowski S. Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase. Eur. J. Biochem. 244:1997;664-673.
20. Wang R., Newton D.J., Liu N., Atkins W.M., Lu A.Y.H. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab. Dispos. 28:1999;360-366.